💊 P&G Health Q2 FY2025-26 Results: Profit Up ~8% YoY, Sales Edge Higher +3%—Margin Poise Intact, Brand Engine Humming

P&G Health (NSE: PGHL) delivered a steady second quarter for FY26. Revenue ticked up modestly year-on-year, and profit rose faster than sales—thanks to disciplined execution and continued brand strength in core vitamins/minerals & OTC categories.

According to exchange-reported figures, Q2 FY26 total income stood at ~₹329.9 crore and PAT at ~₹88.5 crore, up mid-single digit and high-single digit YoY, respectively. QoQ, revenue softened a touch, but profit improved sharply as costs normalized. EquityBulls Business Standard summarized the print as profit +8% YoY to ~₹89 crore; sales +3% YoY, citing brand momentum and incremental innovations. Business Standard

🧾 Snapshot: Three-way Comparison

*Different trackers label “sales” vs “total income” slightly differently; company-level data show sales ~₹3,249.2 mn and revenue/total income ~₹3,298.7 mn for Q2 FY26; we therefore quote a range where relevant and cite both sources. MarketScreener

📌 What Stood Out This Quarter

1) Profits growing faster than sales

With sales up ~3–4% YoY and PAT up ~8%, operating discipline and mix did the heavy lifting. Press coverage ties the outperformance to “brand strength, new launches, and supply chain gains.” Business Standard

2) QoQ swing: revenue down, profit up

Versus Q1, total income slipped (~₹342.8 cr → ₹329.9 cr), yet PAT jumped (~₹66.2 cr → ₹88.5 cr). That implies better cost containment and/or a richer product mix in Q2. EquityBulls

3) Margin poise intact

While the company doesn’t publish EBITDA in the press round-ups, the PAT delta against modest top-line growth suggests stable to improving operating leverage—a healthy sign given category competition.

🧬 Business Context: Where Growth Is Coming From

P&G Health in India operates a focused portfolio anchored in vitamins, minerals & supplements and OTC remedies (e.g., B-complex and vitamin E brands, cod liver oil, nasal decongestants)—franchises that rely on doctor trust, pharmacist pull, and strong brand recall. (See the company’s media/investor pages for category cues and quarterly performance updates.) pghealthindia.com+1

Growth drivers in Q2 FY26 (as reflected by results/coverage):

• Core brands staying resilient: Sustained consumption and high repeat rates in daily-use health supplements translate into predictable base sales. Business Standard

• Product innovation & pack/price architecture: Incremental innovations and portfolio refresh support pricing power and premiumization. Business Standard

• Supply chain efficiencies: Better availability and service levels can add a few points to sell-out momentum while protecting gross margins. Business Standard

🔎 Deeper Financial Read-Through

Revenue: Mid-single digit YoY lift

• YoY: ~₹316.7 cr → ~₹329.9 cr total income (~4%), or sales up ~3% by Business Standard’s framing. EquityBulls+1

• QoQ: ~₹342.8 cr → ~₹329.9 cr (–3.8%). The sequential step-down likely reflects trade phasing after a strong Q1 (company disclosed +20% sales in the June quarter on its media page). pghealthindia.com

Profit: High-single digit YoY

• PAT: ~₹82.3 cr → ₹88.5 cr YoY (~+7.5%); QoQ: ₹66.2 cr → ₹88.5 cr (~+34%). EPS mirrors the step-up (₹49.6 → ₹53.34 YoY; ₹39.87 → ₹53.34 QoQ). EquityBulls

Mix & Efficiency

• The PAT > Sales growth gap points to mix improvements (premium SKUs, Rx-to-OTC strength) and tight OPEX. Coverage explicitly credits brand strength + supply chain gains. Business Standard

🧭 Management Signals & Guidance Hints

While the company’s Q2 media interactions were concise, the signals were clear in coverage:

• Steady growth posture: Management tone remains constructive; Business Standard highlights brand fundamentals and new product traction as the pillars behind the Q2 print. Business Standard

• Execution focus: With Q1’s very strong growth base and Q2’s profit-led beat, expect continued emphasis on in-market execution, distribution depth, and medical engagement.

• Innovation cadence: Expect low-risk, high-frequency innovation (line extensions, formats, fortification), sustaining premium tiers without over-stretching affordability. Business Standard

Bottom line from coverage: “Steady second-quarter growth driven by brand strength, new product launches, and supply chain gains.” Business Standard

🧮 Clean Table: Metrics You’ll Want to Quote

(Use “Total income” where the company’s filing is the basis; cite “sales” where third-party trackers refer to it.)

🧠 What This Means for Investors & Observers

1. Quality of growth > quantity of growth
   A high-single digit PAT rise on a ~3–4% sale lift reflects mix & margin quality—a hallmark of consumer-health franchises.

2. Visibility into H2
   Healthcare consumption is non-discretionary, and seasonal upticks (respiratory) can help. With brand engines humming, H2 should stay resilient, absent macro shocks.

3. Pricing power & innovation
   Low-volatility categories (VMS/OTC) plus innovation cadence → pricing power that protects gross margins.

4. Watch list

   • Input costs (vitamins & excipients) if commodity volatility returns.

   • Regulatory actions on OTC/Rx pricing.

   • Competitive intensity from MNCs and local challengers.

🧭 Our Read on the Road Ahead (FY26–FY27)

• Single-digit to low-double-digit sales CAGR looks reasonable for FY26–FY27, powered by core franchises + innovation.

• Operating leverage should support margins, provided A&P stays targeted and supply chain remains efficient.

• Cash generation likely remains robust; PGHL’s capital-light model typically converts earnings to cash efficiently, favoring consistent dividends (subject to board decisions).

🧩 TL;DR

• Q2 FY26: Sales/total income ~₹330 cr; PAT ~₹88.5 cr.

• YoY: Sales +3–4%, Profit +~8%.

• QoQ: Sales −3.8%, Profit +~34% (profitability strengthened).

• Narrative: Brand strength, innovation, supply chain execution drove the steady print; margin discipline evid